Isavuconazole: A new extended spectrum triazole for invasive mold diseases

Michelle R Ananda-Rajah, Dimitrios Kontoyiannis

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)

Abstract

Isavuconazole is the first broad spectrum prodrug triazole with efficacy against invasive fungal diseases including aspergillosis and mucormycosis. Characteristics include linear dose-proportional pharmacokinetics, intravenous and oral formulations allowing therapeutic streamlining, once daily dosing, absence of nephrotoxic solubilizing agents and excellent oral bioavailability independent of prandial status and gastric acidity. An open label noncomparator study demonstrated encouraging results for isavuconazole as primary or salvage therapy for a range of fungi including mucormycosis. Isavuconazole had fewer premature drug discontinuations and adverse events in the eye, hepatobiliary and psychiatry systems than the comparator agent, voriconazole in a randomized double-blind clinical trial. Cross-resistance of isavuconazole best correlates with voriconazole. In vitro resistance is not invariably predictive of clinical failure. Isavuconazole signals progress in pharmacokinetics, bioavailability and toxicity/tolerability supported by clinical efficacy from Phase III trials.

Original languageEnglish
Pages (from-to)693-708
Number of pages16
JournalFuture Microbiology
Volume10
Issue number5
DOIs
Publication statusPublished - 1 May 2015
Externally publishedYes

Keywords

  • invasive aspergillosis
  • invasive fungal infections
  • isavuconazole
  • mucormycosis

Cite this

@article{030f3083ce0640a5a50a0023ec2e867a,
title = "Isavuconazole: A new extended spectrum triazole for invasive mold diseases",
abstract = "Isavuconazole is the first broad spectrum prodrug triazole with efficacy against invasive fungal diseases including aspergillosis and mucormycosis. Characteristics include linear dose-proportional pharmacokinetics, intravenous and oral formulations allowing therapeutic streamlining, once daily dosing, absence of nephrotoxic solubilizing agents and excellent oral bioavailability independent of prandial status and gastric acidity. An open label noncomparator study demonstrated encouraging results for isavuconazole as primary or salvage therapy for a range of fungi including mucormycosis. Isavuconazole had fewer premature drug discontinuations and adverse events in the eye, hepatobiliary and psychiatry systems than the comparator agent, voriconazole in a randomized double-blind clinical trial. Cross-resistance of isavuconazole best correlates with voriconazole. In vitro resistance is not invariably predictive of clinical failure. Isavuconazole signals progress in pharmacokinetics, bioavailability and toxicity/tolerability supported by clinical efficacy from Phase III trials.",
keywords = "invasive aspergillosis, invasive fungal infections, isavuconazole, mucormycosis",
author = "Ananda-Rajah, {Michelle R} and Dimitrios Kontoyiannis",
year = "2015",
month = "5",
day = "1",
doi = "10.2217/fmb.15.34",
language = "English",
volume = "10",
pages = "693--708",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine",
number = "5",

}

Isavuconazole : A new extended spectrum triazole for invasive mold diseases. / Ananda-Rajah, Michelle R; Kontoyiannis, Dimitrios.

In: Future Microbiology, Vol. 10, No. 5, 01.05.2015, p. 693-708.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Isavuconazole

T2 - A new extended spectrum triazole for invasive mold diseases

AU - Ananda-Rajah, Michelle R

AU - Kontoyiannis, Dimitrios

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Isavuconazole is the first broad spectrum prodrug triazole with efficacy against invasive fungal diseases including aspergillosis and mucormycosis. Characteristics include linear dose-proportional pharmacokinetics, intravenous and oral formulations allowing therapeutic streamlining, once daily dosing, absence of nephrotoxic solubilizing agents and excellent oral bioavailability independent of prandial status and gastric acidity. An open label noncomparator study demonstrated encouraging results for isavuconazole as primary or salvage therapy for a range of fungi including mucormycosis. Isavuconazole had fewer premature drug discontinuations and adverse events in the eye, hepatobiliary and psychiatry systems than the comparator agent, voriconazole in a randomized double-blind clinical trial. Cross-resistance of isavuconazole best correlates with voriconazole. In vitro resistance is not invariably predictive of clinical failure. Isavuconazole signals progress in pharmacokinetics, bioavailability and toxicity/tolerability supported by clinical efficacy from Phase III trials.

AB - Isavuconazole is the first broad spectrum prodrug triazole with efficacy against invasive fungal diseases including aspergillosis and mucormycosis. Characteristics include linear dose-proportional pharmacokinetics, intravenous and oral formulations allowing therapeutic streamlining, once daily dosing, absence of nephrotoxic solubilizing agents and excellent oral bioavailability independent of prandial status and gastric acidity. An open label noncomparator study demonstrated encouraging results for isavuconazole as primary or salvage therapy for a range of fungi including mucormycosis. Isavuconazole had fewer premature drug discontinuations and adverse events in the eye, hepatobiliary and psychiatry systems than the comparator agent, voriconazole in a randomized double-blind clinical trial. Cross-resistance of isavuconazole best correlates with voriconazole. In vitro resistance is not invariably predictive of clinical failure. Isavuconazole signals progress in pharmacokinetics, bioavailability and toxicity/tolerability supported by clinical efficacy from Phase III trials.

KW - invasive aspergillosis

KW - invasive fungal infections

KW - isavuconazole

KW - mucormycosis

UR - http://www.scopus.com/inward/record.url?scp=84929747516&partnerID=8YFLogxK

U2 - 10.2217/fmb.15.34

DO - 10.2217/fmb.15.34

M3 - Article

C2 - 26000646

AN - SCOPUS:84929747516

VL - 10

SP - 693

EP - 708

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

IS - 5

ER -